Article

Novel *N*-Heterocyclic Carbene Silver(I) Complexes: Synthesis, Structural Characterization, Antimicrobial and Cytotoxicity Potential Studies

Ichraf Slimani,[a] Ahlem Chakchouk-Mtibaa,[b] Lotfi Mellouli,[b] Lamjed Mansour,[c]
Ismail Ozdemir,[d] Nevin Gürbüz[d] and Naceur Hamdi [ORCID] *,[a]

[a]Research Laboratory of Environmental Sciences and Technologies (LR16ES09),
Higher Institute of Environmental Sciences and Technology, University of Carthage,
BP 77-1054 Hammam-Lif, Tunisia

[b]Laboratory of Microorganisms and Biomolecules, Center of Biotechnology of Sfax,
Road of Sidi Mansour, km 6, P.O. Box 1117, 3018 Sfax, Tunisia

[c]Zoology Department, College of Science, King Saud University, P.O. Box 2455, 11451 Riyadh,
Saudi Arabia

[d]Department of Chemistry, Faculty of Science and Art, İnönü University,
44000 Malatya, Turkey

In this study, a series of unsymmetrical *N*,*N*-disubstituted benzimidazolium salts were synthesized as *N*-heterocyclic carbene (NHC) (**2a**-**2j**) and their Ag[I] complexes. Their structures were characterized by elemental analyses, ^{1}H and ^{13}C nuclear magnetic resonance (NMR) and infrared (IR) spectroscopy techniques. Further, both the salts and their silver(I)-NHC complexes have been evaluated for their potential antibacterial properties against a panel of bacterial strains namely, *Micrococcus luteus*, *Listeria monocytogenes*, *Salmonella* Typhimurium, *Staphylococcus aureus* and *Pseudomonas aeruginosa*. The results show that silver complexes are effective against *Salmonella* Typhimurium, *Listeria monocytogenes*, and *Micrococcus luteus* with moderate to high activity, and their minimum inhibitory concentrations ranging from 0.0034 to 1.26 mg mL^{-1}. In addition, the benzimidazoles salts **2a**-**2j** and silver-NHC complexes **3a**-**3j** were screened for their antitumor activity. Complex **3e** exhibited the highest antitumor effect with half-maximal inhibitory concentration (IC$_{50}$) value of 4.2 μg mL^{-1} against MCF-7.

Keywords: *N*-heterocyclic carbene, benzimidazolium salts, silver(I)-NHC complexes, antimicrobial and antitumor activities

Introduction

Organometallic complexes have an important role as design of therapeutic agents in biomedical applications. Organometallic compounds with *N*-heterocyclic carbene (NHC) ligands have been used in organic transformations and metal-based drugs lately.[1,2] The performance of organometallic compound in medical applications may closely be related to the choice of convenient ligands, and is crucially dependent on the respective trace metal binding forms.[3] Heterocyclic azoles, such as imidazole, triazole, and especially benzimidazole have significant biological activities.[4-7] Especially, NHC derived from the imidazole or benzimidazole core have considerable antibacterial or anticancer activities.[8-13] NHCs are also a well-known class of organometallic ligands which are a strong σ-donating and weak π-accepting when connected with metal ions. Metal-NHC complexes have exhibited an interesting propensity to bind deoxyribonucleic acid (DNA) by means of non-covalent interactions, which is believed to partially mediate their anti-proliferative activity, and to cleave DNA strands.[14-17] In addition to their antimicrobial and anticancer activity, metal-NHC complexes have also been intensely investigated due to their noteworthy applications in catalysis.[18-21] Silver has lower toxicity as compared to other transition metals. One reason for this could be the slower rate of release of silver ions, from the organometallic complexes, which also enhanced their biological activity. Among the many developed anticancer agents consisting of organometallic compounds, those based on silver-NHC

*e-mail: naceur.hamdi@isste.rnu.tn

complexes have attracted much attention because of their biological properties such as antimicrobial, anticancer, and antibacterial activities.[22-27] Ag-NHC complexes have been suggested as antimicrobial agents to prevent infections, in wound care antiseptics and in water purification.[28,29] Metallic silver was used as a treatment for gonorrhea before the development of antibiotics, while silver nitrate was commonly used as an antimicrobial compound before the discovery of penicillin in ancient times.[30] Silver nitrate is still being used as a preventive drug against the development of neonatal conjunctivitis in infants. The aim of this study was to design novel NHC salts and their Ag[I] complexes and investigate their antimicrobial and cytotoxic activities. All salts and complexes structures were characterized by elemental analysis, Fourier transform infrared (FTIR), ^{1}H and ^{13}C nuclear magnetic resonance (NMR) spectroscopies.

Experimental

Materials and methods

All procedures were carried out under an inert atmosphere using standard Schlenk line techniques. Chemicals and solvents were purchased from Sigma-Aldrich (Istanbul, Turkey). The solvents used were purified and dried by MBraun SPS 800 solvent purification system. Column chromatography was performed by using silica gel 60 (70-230 mesh). ^{1}H and ^{13}C NMR spectra were recorded at 400 MHz (^{1}H), 100 MHz (^{13}C) in CDCl$_3$ with tetramethylsilane as an internal reference. The NMR studies were carried out in high-quality 5 mm NMR tubes. Signals are quoted in parts *per* million as δ downfield from tetramethylsilane ($\delta = 0.00$) as an internal standard. NMR multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, m = multiplet. Gas chromatography (GC) analyses of reactions mixtures were done using a Shimadzu GC 2010-Plus GCFID system. Column: TeknokromaTRB-5 capillary column, 30 m × 0.32 mm × 0.25 μm. Initial temperature at 50 °C, held for 1 min, ramp 2 °C min⁻¹ until 90 °C, held for 3 min, ramp 40 °C min⁻¹ until 240 °C, held for 10 min. The temperature of the injector and detector were held at 240 °C. Melting points (mp) were determined with Kofler bench at Isste of Borj Cedria (Hammam-Lif, University of Carthage, Borj Cedria, Tunisia).

General procedure for the preparation of benzimidazolium salts

The benzimidazolium salts **2a**-**2j** were prepared by reacting *N*-(isobutyl)-benzimidazole (1 mmol) (**1**) with various alkyl chloride (1.1 mmol) in dimethylformamide (DMF; 5 mL) at 80 °C and the resulting mixture was stirred for 24 h. Diethyl ether (15 mL) was added to obtain a white crystalline solid, which was subsequently filtered off. The solid was washed with diethyl ether (3 × 10 mL), dried under vacuum, and the crude product was recrystallized from dichloromethane/diethyl ether (1:3 ratio).

1-(Isobutyl)-3-(3,4,5-trimethoxylbenzyl)benzimidazolium chloride (2a)

Yield: 93%; mp 136.2 °C; IR (KBr) ν / cm⁻¹ 1437; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.01 (d, 6H, CH$_{3a,b}$), 2.39 (hept, 1H, H$_{2'}$, *J* 4 Hz), 3.78 (s, 6H, CH$_{3c,e}$), 3.84 (s, 3H, CH$_{3d}$), 4.40 (d, 2H, H$_{1'}$, *J* 4 Hz), 5.81 (s, 2H, H$_{1''}$), 6.88 (s, 2H, H$_{3'',7''}$), 7.57-7.74 (m, 4H, H$_{4,5,6,7}$), 12.02 (s, 1H, H$_2$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.9 (C$_{a,b}$), 28.9 (C$_{2'}$), 51.6 (C$_{1''}$), 54.5 (C$_{1'}$), 56.7 (C$_{c,e}$), 60.9 (C$_d$), 106.1 (C$_{3'',7''}$), 113.2 (C$_4$), 113.8 (C$_7$), 127.2 (C$_5$), 128.6 (C$_6$), 131.2 (C$_8$), 131.7 (C$_9$), 138.6 (C$_{5''}$), 144.1 (C$_{2,2'}$), 153.9 (C$_{4'',6''}$).

1-(Isobutyl)-3-(3,4,5-trimethoxylbenzyl)-5,6-dimethyl-benzimidazolium chloride (2b)

Yield: 92%; mp 198.2 °C; IR (KBr) ν / cm⁻¹ 1438; ^{1}H NMR (400 MHz, CDCl$_3$) δ 0.98 (d, 6H, CH$_{3a,b}$, *J* 8 Hz), 2.34 (hept, 1H, H$_{2'}$, *J* 8 Hz), 2.37 (d, 6H, CH$_{3c,d}$, *J* 4 Hz), 3.75 (s, 3H, CH$_{3f}$), 3.81 (s, 6H, CH$_{3e,g}$), 4.30 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.71 (s, 2H, H$_{1''}$), 6.82 (s, 2H, H$_{3'',7''}$), 7.35 (s, 1H, H$_4$), 7.42 (s, 1H, H$_7$), 11.80 (s, 1H, H$_2$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.7 (C$_{c,d}$), 20.7 (C$_{a,b}$), 28.7 (C$_{2'}$), 51.2 (C$_{1''}$), 54.3 (C$_{1'}$), 56.6 (C$_{e,g}$), 60.8 (C$_f$), 105.9 (C$_{3'',7''}$), 112.8 (C$_4$), 113.4 (C$_7$), 128.8, (C$_{2''}$), 129.65 (C$_8$), 130.1 (C$_9$), 137.3 (C$_{5,6}$), 138.4 (C$_{5''}$), 142.7 (C$_2$), 153.7 (C$_{4'',6''}$).

1-(Isobutyl)-3-(4-*tert*-butylbenzyl)benzimidazolium chloride (2c)

Yield: 97%; mp 217.2 °C; IR (KBr) ν / cm⁻¹ 1542; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.03 (d, 6H, CH$_{3a,b}$), 1.23 (s, 9H, CH$_{3c,d,e}$), 2.44 (hept, 1H, H$_{2'}$, *J* 8 Hz), 4.40 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.84 (s, 2H, H$_{1''}$), 7.33-7.67 (m, 8H, H$_{4,5,6,7,3'',4'',6'',7''}$), 12.0 (s, 1H, H$_2$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.3 (C$_{a,b}$), 28.6 (C$_{2'}$), 30.9 (C$_{c,d,e}$), 34.4 (C$_{8''}$), 51.8 (C$_{1''}$), 54.1 (C$_{1'}$), 112.8 (C$_4$), 113.6 (C$_7$), 126.0 (C$_{4'',6''}$), 126.7 (C$_5$), 126.8 (C$_6$), 127.7 (C$_{3'',7''}$), 129.6 (C$_{2''}$), 130.9 (C$_8$), 131.5 (C$_9$), 143.7 (C$_2$), 152.0 (C$_{5''}$).

1-(Isobutyl)-3-(4-*tert*-butylbenzyl)-5,6-dimethyl-benzimidazolium chloride (2d)

Yield: 98%; mp 243.2 °C; IR (KBr) ν / cm⁻¹ 1558; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.01 (d, 6H, CH$_{3a,b}$, *J* 8 Hz), 1.23 (s, 9H, CH$_{3c,d,e}$), 2.36 (s, 3H, CH$_{3c}$), 2.39 (s, 3H, CH$_{3d}$), 2.52 (hept, 1H, H$_{2'}$, *J* 8 Hz), 4.32 (d, 2H, H$_{2'}$, *J* 8 Hz), 5.76

(s, 2H, $H_{1''}$), 7.32-7.39 (m, 6H, $H_{4,7,3'',4'',6'',7''}$), 11.77 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.9 ($C_{a,b}$), 20.7 ($C_{c,d}$), 28.8 ($C_{2'}$), 31.2 ($C_{e,f,g}$), 34.7 ($C_{8''}$), 50.8 ($C_{1''}$), 54.3 ($C_{1'}$), 112.8 (C_4), 113.4 (C_7), 126.2 ($C_{4'',6''}$), 127.9 ($C_{3'',7''}$), 129.8 ($C_{5,6}$), 130.2 (C_8), 130.3 (C_9), 137.2 ($C_{2''}$), 127.87 ($C_{8,9}$), 142.80 (C_2), 152.30 ($C_{5''}$).

1-(Isobutyl)-3-(2,4,6-trimethylbenzyl)benzimidazolium chloride (2e)

Yield: 94%; mp 218.3 °C; IR (KBr) ν / cm^{-1} 1469; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.00 (d, 6H, $CH_{3a,b}$, *J* 8 Hz), 2.25 (s, 3H, CH_{3d}), 2.28 (s, 6H, $CH_{3c,e}$), 2.37 (hept, 1H, $H_{2'}$, *J* 8 Hz), 4.42 (d, 2H, $H_{1'}$, *J* 8 Hz), 5.90 (s, 2H, $H_{1''}$), 6.88 (s, 2H, $H_{4'',6''}$), 7.10 (d, 1H, H_4, *J* 8 Hz), 7.37 (t, 1H, H_5, *J* 8 Hz), 7.51 (t, 1H, H_6, *J* 8 Hz), 7.64 (d, 1H, H_7, *J* 8 Hz), 11.61 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.8 ($C_{c,e}$), 20.3 ($C_{a,b}$), 21.1 (C_d), 28.9 ($C_{2'}$), 47.5 ($C_{1''}$), 54.3 ($C_{1'}$), 113.1 (C_4), 114.0 (C_7), 125.2 ($C_{5,6}$), 126.9 ($C_{4''}$), 127.1 ($C_{6''}$), 130.2 (C_8), 131.3 (C_9), 131.8 ($C_{3''}$), 137.9 ($C_{5'',7''}$), 139.6 ($C_{2''}$), 144.2 (C_2).

1-(Isobutyl)-3-(4-methylbenzyl)-5,6-dimethyl-benzimidazolium chloride (2f)

Yield: 93%; mp 223.2 °C; IR (KBr) ν / cm^{-1} 1561; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.02 (d, 6H, $CH_{3a,b}$, *J* 8 Hz), 2.27 (s, 3H, CH_{3e}), 2.34 (s, 3H, CH_{3c}), 2.35 (hept, 1H, $H_{2'}$, *J* 4 Hz), 2.38 (s, 3H, CH_{3d}), 4.31 (d, 2H, $H_{1'}$, *J* 8 Hz), 5.70 (s, 2H, $H_{1''}$), 7.11 (d, 2H, $H_{5,6}$, *J* 8 Hz), 7.30-7.35 (m, 2H, $H_{3'',4'',6'',7''}$), 11.79 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.8 ($C_{a,b}$), 20.7 ($C_{c,d}$), 21.2 (C_e), 28.8 ($C_{2'}$), 50.9 ($C_{1''}$), 54.2 ($C_{1'}$), 112.8 (C_4), 113.4 (C_7), 128.18 ($C_{5,6}$), 129.7 ($C_{5''}$), 129.9 ($C_{3'',7''}$), 130.2 ($C_{4'',6''}$), 130.2 (C_8), 137.2 (C_9), 139.0 ($C_{2''}$), 142.8 (C_2).

1-(Isobutyl)-3-(naphthyl)benzimidazolium chloride (2g)

Yield: 89%; mp 146.4 °C; IR (KBr) ν / cm^{-1} 1665; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.04 (d, 6H, $CH_{3a,b}$, *J* 8 Hz), 2.42 (hept, 1H, $H_{2'}$, *J* 8 Hz), 4.41 (d, 2H, $H_{1'}$, *J* 8 Hz), 6.08 (s, 2H, $H_{1''}$), 7.45-7.99 (m, 11H, $H_{4,5,6,7,3'',5'',6'',7'',8'',10'',11''}$), 12.15 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.9 ($C_{a,b}$), 28.9 ($C_{2'}$), 51.7 ($C_{1''}$), 54.5 ($C_{1'}$), 113.1 (C_4), 114.0 (C_7), 125.3 ($C_{7''}$), 126.8 (C_5), 127.0 (C_6), 127.1 ($C_{3''}$), 127.2 ($C_{10''}$), 127.8 ($C_{5''}$), 128.2 ($C_{8''}$), 129.6 ($C_{6''}$), 130.4 ($C_{11''}$), 131.2 ($C_{2''}$), 131.8 ($C_{4''}$), 131.15 ($C_{9''}$), 133.1 (C_8), 133.3 (C_9), 144.15 (C_2).

1-(Isobutyl)-3-(anthracen-9-ylmethyl)benzimidazolium chloride (2h)

Yield: 89%; mp 278.9 °C; IR (KBr) ν / cm^{-1} 1550; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.02 (d, 6H, $CH_{3a,b}$, *J* 8 Hz), 2.34 (hept, 1H, $H_{2'}$, *J* 8 Hz), 4.37 (d, 2H, $H_{1'}$, *J* 4 Hz), 6.95

(s, 2H, $H_{1''}$), 7.03-8.54 (m, 13H, $H_{4,5,6,7,4'',5'',6'',7'',9'',11'',12'',13'',14''}$), 12.27 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.8 ($C_{a,b}$), 28.8 ($C_{2'}$), 45.6 ($C_{1''}$), 54.4 ($C_{1'}$), 112.8 (C_4), 114.4 (C_7), 121.8 ($C_{9''}$), 123.0 ($C_{6'',12''}$), 125.5 ($C_{5'',13''}$), 126.6 (C_5), 126.8 (C_6), 128.3 ($C_{4'',14''}$), 129.8 ($C_{7'',11''}$), 130.7 ($C_{4'',15''}$), 131.0 ($C_{8,9}$), 131.3 ($C_{8'',10''}$), 131.4 ($C_{10''}$), 131.7 ($C_{2''}$), 144.5 (C_2).

1-(Isobutyl)-3-(methoxyethyl)benzimidazolium chloride (2i)

Yield: 77%; mp 108.5 °C; IR (KBr) ν / cm^{-1} 1567; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.01 (d, 6H, $CH_{3a,b}$, *J* 8 Hz), 2.38 (hept, 1H, $H_{2'}$, *J* 8 Hz), 3.30 (s, 3H, CH_{3c}), 3.91 (t, 3H, $H_{2''}$, *J* 4 Hz), 4.38 (d, 2H, $H_{1'}$, *J* 8 Hz), 4.87 (t, 2H, $H_{1''}$, *J* 8 Hz), 7.58-7.84 (m, 4H, $H_{4,5,6,7}$), 11.46 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.8 ($C_{a,b}$), 28.9 ($C_{2'}$), 47.7 ($C_{1''}$), 54.3 (C_c), 59.1 ($C_{1'}$), 70.5 ($C_{2''}$), 112.8 (C_4), 114.2 (C_7), 126.9 ($C_{5,6}$), 131.4 (C_8), 132.1 (C_9), 143.9 (C_2).

1-(Isobutyl)-3-(isobutyl)-5,6-dimethylbenzimidazolium chloride (2j)

Yield: 87%; mp 127.9 °C; IR (KBr) ν / cm^{-1} 1666; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.01 (d, 12H, $CH_{3a,b,c,d}$, *J* 4 Hz), 2.39 (hept, 2H, $H_{2',2''}$, *J* 8 Hz), 2.44 (s, 6H, $CH_{3e,f}$), 4.39 (d, 4H, $H_{1',1''}$, *J* 8 Hz), 7.41 (s, 2H, $H_{4,7}$), 11.26 (s, 1H, H_2); ^{13}C NMR (100 MHz, CDCl$_3$) δ 19.8 ($C_{a,b,c,d}$), 20.7 ($C_{e,f}$), 28.9 ($C_{2',2''}$), 54.1 ($C_{1',1''}$), 112.9 ($C_{4,7}$), 130.0 ($C_{8,9}$), 137.4 ($C_{5,6}$), 142.1 (C_2).

General procedure for the preparation of silver(I)-NHC complexes

A solution of benzimidazolium salt (1.0 mmol) and Ag$_2$O (1.0 mmol) in dichloromethane (15 mL) was stirred at room temperature for 24 h. The reaction mixture was filtered through celite and the solvent removed under reduced pressure. The crude product was recrystallized from dichloromethane/diethyl ether (1:3).

Chloro[1-(isobutyl)-3-(3,4,5-trimethoxylbenzyl)benzimidazole-2-ylidene]silver(I) (3a)

Yield: 75%; mp 136.2 °C; IR (KBr) ν / cm^{-1} 1567; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.00 (d, 6H, $CH_{3a,b}$, *J* 4 Hz), 2.36 (hept, 1H, $H_{2'}$, *J* 4 Hz), 3.78 (s, 6H, $CH_{3c,e}$), 3.80 (s, 3H, CH_{3d}), 4.25 (d, 2H, $H_{1'}$, *J* 8 Hz), 5.52 (s, 2H, $H_{1''}$), 6.50 (s, 2H, $H_{3'',7''}$), 7.33-7.49 (m, 4H, $H_{4,5,6,7}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.3 ($C_{a,b}$), 29.4 ($C_{2'}$), 53.5 ($C_{1''}$), 56.4 ($C_{c,e}$), 56.9 ($C_{1'}$), 61.0 (C_d), 104.5 ($C_{3'',7''}$), 111.9 (C_4), 112.1 (C_7), 124.4 (C_5), 124.5 (C_6), 130.6 ($C_{2''}$), 133.8 (C_8), 134.2 (C_9), 138.2 ($C_{5''}$), 153.8 ($C_{4'',6''}$); elemental analysis calcd. for C$_{21}$H$_{26}$AgClN$_2$O$_3$: C 50.67, H 5.26, N 5.62%, found: C 50.1, H 5.4, N 5.8%.

Chloro[1-(isobutyl)-3-(3,4,5-trimethoxybenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (3b)

Yield: 92%; mp 289.5 °C; IR (KBr) ν / cm^{-1} 1583; ^{1}H NMR (400 MHz, CDCl$_3$) δ 0.99 (d, 6H, CH$_{3a,b}$, *J* 8 Hz), 2.34 (s, 6H, CH$_{3c}$), 2.35 (hept, 1H, H$_{2'}$), 2.38 (s, 6H, CH$_{3d}$), 3.78 (s, 6H, CH$_{3e,g}$), 3.81 (s, 3H, CH$_{3f}$), 4.18 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.45 (s, 2H, H$_{1''}$), 6.45 (s, 2H, H$_{3'',7''}$), 7.15 (s, 1H, H$_4$), 7.21 (s, 1H, H$_7$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.3 (C$_{c,d}$), 20.5 (C$_{a,b}$), 29.3 (C$_{2'}$), 53.3 (C$_{1''}$), 56.3 (C$_{e,g}$), 56.8 (C$_{1'}$), 61.0 (C$_f$), 104.4 (C$_{3'',7''}$), 112.0 (C$_4$), 112.2 (C$_7$), 130.9 (C$_{2''}$), 132.4 (C$_8$), 132.7 (C$_9$), 138.45 (C$_{5''}$), 133.8 (C$_5$), 133.9 (C$_6$), 138.1 (C$_2$), 153.8 (C$_{4'',6''}$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{23}$H$_{30}$AgClN$_2$O$_3$: C 52.53, H 5.75, N 5.32%, found: C 52.7, H 5.9, N 5.5%.

Chloro[1-(isobutyl)-3-(4-*tert*-butylbenzyl)benzimidazole-2-ylidene]silver (3c)

Yield: 78%; mp 108.6 °C; IR (KBr) ν / cm^{-1} 1450; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.02 (d, 6H, CH$_{3a,b}$, *J* 8 Hz), 1.27 (s, 9H, CH$_{3c,d,e}$), 2.36 (hept, 1H, H$_{2'}$, *J* 8 Hz), 4.24 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.58 (s, 2H, H$_{1''}$), 7.17-7.48 (m, 8H, H$_{4,5,6,7,3'',4'',6'',7''}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.4 (C$_{a,b}$), 29.4 (C$_{2'}$), 31.3 (C$_{c,d,e}$), 34.7 (C$_{8''}$), 53.1 (C$_{1''}$), 56.9 (C$_{1'}$), 111.7 (C$_4$), 112.3 (C$_7$), 124.2 (C$_{4''}$), 124.3 (C$_{6''}$), 126.1 (C$_{5,6}$), 126.9 (C$_{3'',7''}$), 131.9 (C$_{2''}$), 133.8 (C$_8$), 134.3 (C$_9$), 151.7 (C$_{5''}$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{22}$H$_{28}$AgClN$_2$: C 56.97, H 6.08, N 6.04%, found: C 57.1, H 6.1, N 6.3%.

Chloro[1-(isobutyl)-3-(4-*tert*-butylbenzyl)-5,6-dimethyl-benzimidazole-2-ylidene]silver(I) (3d)

Yield: 79%; mp 118.2 °C; IR (KBr) ν / cm^{-1} 1450; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.01 (d, 6H, CH$_{3a,b}$, *J* 4 Hz), 1.28 (s, 9H, CH$_{3c,d,e}$), 2.32 (s, 3H, CH$_{3c}$), 2.35 (hept, 1H, H$_{2'}$, *J* 8 Hz), 2.37 (s, 3H, CH$_{3d}$), 4.16 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.51 (s, 2H, H$_{1''}$), 7.12-7.34 (m, 6H, H$_{4,7,3'',4'',6'',7''}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.4 (C$_{c,d}$), 20.5 (C$_a$), 20.6 (C$_b$), 29.3 (C$_{2'}$), 31.3 (C$_{e,f,g}$), 34.7 (C$_{8''}$), 52.9 (C$_{1''}$), 56.8 (C$_{1'}$), 111.9 (C$_4$), 112.4 (C$_7$), 126.1 (C$_{4'',6''}$), 126.7 (C$_{3'',7''}$), 132.2 (C$_{8,9}$), 132.4 (C$_5$), 132.8 (C$_6$), 133.7 (C$_{2''}$), 133.8 (C$_2$), 151.5 (C$_{5''}$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{24}$H$_{32}$AgClN$_2$: C 58.60, H 6.55, N 5.69%, found: C 58.8, H 6.7, N 5.8%.

Chloro[1-(isobutyl)-3-(2,4,6-trimethylbenzyl)benzimidazole-2-ylidene]silver (3e)

Yield: 74%; mp 194.2 °C; IR (KBr) ν / cm^{-1} 1467; ^{1}H NMR (400 MHz, CDCl$_3$) δ 0.95 (d, 6H, CH$_{3a,b}$, *J* 4 Hz), 2.23 (s, 6H, CH$_{3c,e}$), 2.30 (hept, 1H, H$_{2'}$), 2.34 (s, 3H, CH$_{3d}$), 4.19 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.49 (s, 2H, H$_{1''}$), 7.24-7.47 (m, 6H, H$_{4,5,6,7,4'',6''}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.4 (C$_{a,b}$), 20.5 (C$_{c,e}$), 21.3 (C$_d$), 29.4 (C$_{2'}$), 48.0 (C$_{1''}$), 57.4 (C$_{1'}$), 111.7 (C$_4$), 111.8 (C$_7$), 124.1 (C$_5$), 124.3 (C$_6$), 126.7 (C$_{4'',6''}$), 130.4 (C$_{5'',2''}$), 134.2 (C$_8$), 134.3 (C$_9$), 137.5 (C$_{3''}$), 139.6 (C$_{7''}$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{21}$H$_{26}$AgClN$_2$: C 56.07, H 5.82, N 6.22%, found: C 56.1, H 5.9, N 6.3%.

Chloro[1-(isobutyl)-3-(4-methylbenzyl)-5,6-dimethyl-benzimidazole-2-ylidene]silver (3f)

Yield: 93%; mp 161.2 °C; IR (KBr) ν / cm^{-1} 1433; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.00 (d, 6H, CH$_{3a,b}$, *J* 4 Hz), 2.31 (s, 3H, CH$_{3c,d}$), 2.35 (hept, 1H, H$_{2'}$, *J* 8 Hz), 2.36 (s, 3H, CH$_{3e}$), 4.17 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.50 (s, 2H, H$_{1''}$), 7.09-7.19 (m, 6H, H$_{4,7,3'',4'',6'',7''}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.4 (C$_{c,d}$), 20.5 (C$_a$), 20.6 (C$_b$), 21.2 (C$_e$), 29.3 (C$_{2'}$), 53.1 (C$_{1''}$), 56.8 (C$_{1'}$), 111.9 (C$_4$), 112.4 (C$_7$), 127.0 (C$_{3'',7''}$), 129.8 (C$_{4'',6''}$), 132.2 (C$_{2'',5''}$), 133.7 (C$_{8,9}$), 133.8 (C$_5$), 138.3 (C$_6$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{21}$H$_{26}$AgClN$_2$: C 56.07, H 5.82, N 6.22%, found: C 56.1, H 5.9, N 6.3%.

Chloro[1-(isobutyl)-3-(naphthyl)benzimidazole-2-ylidene]silver(I) (3g)

Yield: 76%; mp 195.4 °C; IR (KBr) ν / cm^{-1} 1437; ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.02 (d, 6H, CH$_{3a,b}$, *J* 8 Hz), 2.39 (hept, 1H, H$_{2'}$, *J* 8 Hz), 4.27 (d, 2H, H$_{1'}$, *J* 8 Hz), 5.77 (s, 2H, H$_{1''}$), 7.29-7.80 (m, 11H, H$_{4,5,6,7,3'',5'',6'',7'',8'',10'',11''}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.4 (C$_{a,b}$), 29.5 (C$_{2'}$), 53.9 (C$_{1''}$), 56.9 (C$_{1'}$), 111.8 (C$_4$), 112.4 (C$_7$), 124.3 (C$_5$), 124.4 (C$_6$), 124.5 (C$_{7''}$), 126.5 (C$_{6''}$), 126.7 (C$_{3''}$), 126.8 (C$_{10''}$), 127.9 (C$_{5''}$), 128.0 (C$_{8''}$), 129.3 (C$_{11''}$), 132.3 (C$_{4''}$), 133.3 (C$_{9''}$), 133.3 (C$_8$), 133.7 (C$_9$), 134.4 (C$_{2''}$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{22}$H$_{22}$AgClN$_2$: C 57.72, H 4.84, N 6.12%, found: C 57.9, H 4.9, N 6.3%.

Chloro[1-(isobutyl)-3-(anthracen-9-ylmethyl)benzimidazole-2-ylidene]silver(I) (3h)

Yield: 74%; mp 252.3 °C; IR (KBr) ν / cm^{-1} 1450; ^{1}H NMR (400 MHz, CDCl$_3$) δ 0.95 (d, 6H, CH$_{3a,b}$, *J* 8 Hz), 2.29 (hept, 1H, H$_{2'}$, *J* 8 Hz), 4.16 (d, 2H, H$_{1'}$, *J* 8 Hz), 6.50 (s, 2H, H$_{1''}$), 7.01-7.12 (m, 2H, H$_{5'',6''}$), 7.29 (d, 1H, H$_{4''}$, *J* 8 Hz), 7.40 (d, 1H, H$_{7''}$, *J* 8 Hz), 7.49-7.57 (m, 4H, H$_{4,5,6,7}$), 8.10 (d, 2H, H$_{11'',12''}$), 8.23 (d, 2H, H$_{13'',14''}$, *J* 8 Hz), 8.64 (s, 1H, H$_{9''}$); ^{13}C NMR (100 MHz, CDCl$_3$) δ 20.4 (C$_{a,b}$), 29.4 (C$_{2'}$), 46.9 (C$_{1''}$), 57.3 (C$_{1'}$), 111.7 (C$_4$), 112.3 (C$_7$), 123.0 (C$_{5,6}$), 123.3 (C$_{9''}$), 124.2 (C$_{6'',12''}$), 125.4 (C$_{5'',13''}$), 127.8 (C$_{4'',14'',7'',11''}$), 130.1 (C$_{3'',15''}$), 130.5 (C$_{8'',10''}$), 131.2 (C$_{8,9}$), 131.6 (C$_{2''}$), C$_2$-Ag: not observed; elemental analysis calcd. for C$_{26}$H$_{24}$AgClN$_2$: C 61.49, H 4.76, N 5.51%, found: C 61.6, H 4.9, N 5.8%.

Chloro[1-(isobutyl)-3-(methoxyethyl)benzimidazole-2-ylidene]silver(I) (**3i**)

Yield: 77%; mp 188.5 °C; IR (KBr) ν / cm⁻¹ 1433; ¹H NMR (400 MHz, CDCl₃) δ 0.99 (d, 6H, CH$_{3a,b}$, *J* 4 Hz), 2.33 (hept, 1H, H$_{2'}$, *J* 4 Hz), 3.29 (s, 3H, CH$_{3c}$), 3.79 (t, 3H, H$_{2''}$, *J* 4 Hz), 4.20 (d, 2H, H$_{1'}$, *J* 8 Hz), 4.56 (t, 2H, H$_{1''}$, *J* 8 Hz), 7.37-7.59 (m, 4H, H$_{4,5,6,7}$); ¹³C NMR (100 MHz, CDCl₃) δ 20.4 (C$_{a,b}$), 29.4 (C$_{2'}$), 49.5 (C$_{1'}$), 56.9 (C$_c$), 59.2 (C$_{1'}$), 72.0 (C$_{2''}$), 111.5 (C₄), 112.4 (C₇), 124.1 (C$_{5,6}$), 133.9 (C₈), 134.5 (C₉), C₂-Ag: not observed; elemental analysis calcd. for C₁₄H₂₀AgClN₂O: C 44.76, H 5.36, N 7.45%, found: C 44.8, H 5.5, N 7.6%.

Chloro[1-(isobutyl)-3-(isobutyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (**3j**)

Yield: 72%; mp 168.9 °C; IR (KBr) ν / cm⁻¹ 1600; ¹H NMR (400 MHz, CDCl₃) δ 0.97 (d, 12H, CH$_{3a,b,c,d}$, *J* 8 Hz), 2.33 (hept, 2H, H$_{2',2''}$, *J* 8 Hz), 2.38 (s, 6H, CH$_{3e,f}$), 4.16 (d, 4H, H$_{1',1''}$, *J* 8 Hz), 7.20 (s, 2H, H$_{4,7}$); ¹³C NMR (100 MHz, CDCl₃) δ 20.4 (C$_{a,b,c,d}$), 20.5 (C$_{e,f}$), 29.3 (C$_{2',2''}$), 56.5 (C$_{1',1''}$), 111.9 (C$_{4,7}$), 132.6 (C$_{8,9}$), 133.6 (C$_{5,6}$), 168.7 (C₂); elemental analysis calcd. for C₁₇H₂₆AgClN₂: C 50.82, H 6.52, N 6.97%, found: C 50.9, H 6.9, N 7.2%.

Antibacterial activity

Bacterial strains, media and growth conditions

Bacteria strains used as microorganisms indicator for the antibacterial activity assays were: *Micrococcus luteus* (*M. luteus*) LB 14110, *Staphylococcus aureus* (*S. aureus*) American Type Culture Collection (ATCC) 6538, *Listeria monocytogenes* (*L. monocytogenes*) ATCC 19117, *Salmonella* Typhimurium (*S.* Typhimurium) ATCC 14028, *Pseudomonas aeruginosa* (*P. aeruginosa*) ATCC 49189 and *E. coli* were obtained from International Culture Collections (ATCC) and local culture collection of the Laboratory of Microorganisms and Biomolecules of the Centre of Biotechnology of Sfax, Tunisia.

These bacterial strains were grown overnight in Luria-Bertani (LB) agar medium (g L⁻¹): peptone 10; yeast extract 5 and NaCl 5 at pH 7.2 under aerobic conditions and constant agitation (200 rpm) at 30 °C for *M. luteus* LB14110 and *L. monocytogenes* ATCC 19117 and at 37 °C for *S. aureus* ATCC 6538, *S.* Typhimurium ATCC 14028 and *P. aeruginosa* ATCC 49189, and then diluted 1:100 in LB media and incubated for 5 h under constant agitation (200 rpm) at the appropriate temperature.

Agar well diffusion method

According to Tagg *et al.*[31] with certain adjustments, agar well dissemination technique was employed for the assurance of the antimicrobials activity of synthesized compounds. Growth medium (25 mL) was poured into Petri dishes at 50-70 °C and it was left to solidify under ultraviolet (UV) light (265 nm wavelength) for 15 min. Subsequently, a sterile cotton swab was dipped into overnight bacterial or yeast suspensions of indicator strains (adjusted to turbidity of 0.5 McFarland standard). An agar plate was inoculated by evenly streaking cotton swab over the agar medium. Then wells with a diameter of 8 mm were cut in the medium with a sterile cork borer. Stock solutions of the samples were diluted in sterile distilled water to get 500 μg mL⁻¹ concentrations. The tested samples and controls (100 μL) were dispensed into the wells. The plates were incubated at 37 °C for 24 h. Then the diameters of growth inhibition zones around the wells were measured.

Minimum inhibitory concentration (MIC)

The minimum inhibitory concentration (MIC) of the synthesized compounds was resolved as *per* rules M7-A6[32] and M38-P[33] of National Committee for Clinical Laboratory Standard (NCCLS).[34] The test was conducted in clean 96-well microplates with a final volume in each microplate well of 100 μL. The synthesized compounds (20 mg mL⁻¹) were appropriately arranged in solution of dimethyl sulfoxide (DMSO)/water (1/9; v/v). The inhibitory activity of each synthesized compound was transferred to each well to get a two-fold sequential dilution of the original sample and visible growth after incubation. 25 μL of thiazolyl blue tetrazolium bromide (MTT), indicator solution (0.5 mg mL⁻¹) dissolved in clean water were added to the wells and incubated at room temperature for 30 min. This determination was done in triplicate and the results obtained were fundamentally the same. The detailed value is the average of the three tests.

Antioxidant activity: DPPH radical scavenging activity

Scavenging of 2,2-diphenyl-1-picrylhydrazyl radical (DPPH• examine) is the most generally announced technique for screening antioxidant activity. The methodology includes measurement of decrease in absorbance of DPPH at its assimilation maxima of 517 nm. This test determines the scavenging of stable radical species as indicated by the method of Kirby and Schmidt[35] with slight alterations. Briefly, synthesized compounds were dissolved in DMSO/water (1/9; v/v) and diluted with ultrapure water at different concentrations (1, 0.5, 0.250, 0.125, 0.0625, 0.03125 mg mL⁻¹). Then, 500 μL of a 4% (m/v) solution of DPPH radical in ethanol was mixed with 500 μL of samples. The

mixture was incubated for 30 min in the dark at room temperature. The scavenging capacity was determined spectrophotometrically by monitoring the decrease in absorbance at 517 nm against a blank. The percentage of antiradical activity (ArA) had been calculated as follows:

$$ArA(\%) = [(\text{absorbance of control} - \text{absorbance of test sample}) / \text{absorbance of control}] \times 100 \qquad (1)$$

Cytotoxicity assay

Cytotoxicity of compounds was evaluated through MTT test on MDA-MB-231 and MCF7 cells as recently did by Mosmann *et al.*[36] To be concise, cells were refined into 96-well plates (Corning, USA) at a thickness of 5×10^5 cells for every well in 200 µL medium. After 24 h, cells were treated with various concentrations (10, 5, 2.5, 1 µg mL^{-1}) of compounds and further incubated for 48 h to assess the cytotoxicity of compounds. Toward the finish of the brooding period, 20 µL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) solution was added to each well. An additional 4 h incubation at 37 °C was done, and then the medium was discarded. MeOH treated cells were utilized as controls. The relative cell viability was determined by reading absorbance at 450 nm with a microplate reader. The mean optical density (OD, absorbance) of treated and control wells was used to calculate the percentage of cell viability as follows:

$$\text{Percentage of cell viability (\%)} = (\text{OD treated/OD control}) \times 100 \qquad (2)$$

Standard plate count

Bacterial number in the samples was determined using the standard plate count method. For each dilution series, the sample assumed to have 102 colony-forming unit (CFU) mL^{-1} was used to inoculate Difco tryptic soy agar (TSA) plates (Fort Richard, Auckland, New Zealand). This assumption was based on the optical density of the most concentrated bacterial solution. For each plate count, a 100-µL aliquot of the sample was spread evenly onto a TSA plate and incubated at 37 °C overnight. For each tested sample, duplicate plate counts were made.

Colony-forming unit (CFU) is a measure of viable bacterial or fungal cells. CFU can be calculated using Miles method[37] and it is useful to determine the microbiological load and magnitude of infection in blood and other samples.

Results and Discussion

Preparation of benzimidazolium salts (**2a**-**2j**)

Nitrogen-containing heterocyclic salts have attracted attention in the fields of coordination chemistry due to their metal complexes showing high reactivity as catalyst and biologically agents. In this regards benzimidazolium salts (**2a**-**2j**) were synthesized via the two step *N*-alkylation process as depicted in Scheme 1. Compound **1** was obtained by *N*-alkylation of benzimidazole with isobutyl bromide (1-bromo-2-methylpropane) in the presence of KOH in DMSO. The benzimidazolium salts (**2a**-**2j**) were prepared by reacting *N*-(isobutyl)-benzimidazole (**1**) with various aryl halides in DMF at 80 °C for 24 h (Scheme 1). The reaction has been monitored following thin layer chromatography, and after this time the formation of salts (**2a**-**2j**) has been observed for every target compound. The benzimidazolium salts (**2a**-**2j**) were air- and moisture-stable both in the solid state and in solution.

The FTIR, ^{1}H and ^{13}C NMR spectroscopies, and elemental analysis data of the title compound confirm the proposed structure. NMR spectra of all the compounds were analyzed in *d*-CDCl$_3$. In the ^{1}H NMR spectra, acidic proton (NCHN) for benzimidazolium salts (**2a**-**2j**) were seen at 12.02, 11.80, 12.02, 11.77, 11.61, 11.79, 12.15, 12.27, 11.46 and 11.26 ppm, respectively, as a characteristic sharp singlet. In the ^{13}C NMR spectra of **2a**-**2j**, the characteristic signals of the imino carbon (NCHN) were detected as typical singlets at 144.1, 142.7, 143.7, 142.8, 144.2, 142.8, 144.1, 144.5, 143.9 and 142.1 ppm, respectively. These values are consistent with related literature.[38] The formation of the benzimidazolium salts were also evidenced by their IR spectra, which showed CN bond absorption at 1437, 1438, 1542, 1558, 1469, 1561, 1665, 1550, 1567 and 1666 cm^{-1} for the respective CN bond vibration of **2a**-**2j**.

Aromatic protons of benzimidazolium salts (**2a**-**2j**) were detected in the range of 6.30-8.02 ppm. −CH− protons of isobutyl group on all benzimidazolium salts where seen as heptets in the range of 2.25-2.44 ppm. Methylic protons of isobutyl group on benzimidazolium salts (**2a**-**2j**) were resonated between 0.98 and 1.04 as doublets. In the ^{1}H NMR spectra of **2a**-**2j**, NCH$_2$CH protons appeared as doublet between 4.30 and 4.42 while NCH$_2$C protons were detected as typical singlets between 4.87 and 6.95 (Supplementary Information section).

The ^{13}C NMR spectra showed aromatic carbons of benzimidazolium salts (**2a**-**2j**) in the range of 105.8-153.8 ppm. Terminal carbons of the isobutyl group of all benzimidazolium salts (**2a**-**2j**) gave peaks at 19.9,

Scheme 1. Synthesis of benzimidazoles salts **2a**-**2j**.

19.7, 19.3, 19.9, 19.8, 19.8, 19.9, 19.8, 19.8 and 19.8, respectively, while –CH carbons of the isobutyl group were observed at 28.9, 28.7, 28.6, 28.8, 28.9, 28.8, 28.9, 28.8, 28.9 and 28.9, respectively (Supplementary Information section).

The reaction of the benzimidazolium salt with 1 equiv. Ag_2O in dichloromethane resulted in the silver-NHC complex as a crystalline solid. Monitoring of the reaction by ^{1}H NMR spectroscopy in *d*-CDCl₃ showed that benzimidazolium salts were completely transformed into silver complexes with moderate yields (72-93%) under argon atmosphere. Synthesis of the Ag[I] complexes were conducted in the absence of light and all complexes were stored in the dark (Scheme 2).

The silver complexes are stable in the air and toward the moisture with good solubility in polar solvents. The successful formation of silver carbene complexes was indicated by the absence of a peak of NCHN proton

in their ^{1}H NMR spectra (Figure 1), further suggested full conversion to silver(I) NHC complexes (**3a**-**3j**). In the ^{13}C NMR spectra of **2a**-**2j**, the characteristic signals of carbon (NCHN) were seen as singlets between 142.1-144.2 ppm for benzimidazolium salts while for complexes **3a**-**3j** (Figure 2) a signal of carbon (NCN) have shifted greatly downfield region compared to the corresponding benzimidazolium salt (**2a**-**2j**) and were observed at 186.7 ppm for complex **3j**, however, the rest of carbon signal for the rest of complexes were not observed.

At the same time, formation of the Ag[I]-NHC complexes (**3a**-**3j**) was proven by IR spectra, which showed CN bond vibrations at 1567, 1583, 1450, 1450, 1467, 1433, 1437, 1450, 1433, 1600 cm⁻¹, respectively. The analytical data are in good agreement with the compositions proposed for all the new compounds we prepared and are summarized in Table 1.

Scheme 2. Protocol synthesis of Ag–NHC **3a-3j**.

Asekunowo *et al.*[39] have recently reported the synthesis of a series of mono-carbene silver halides [R₂NHC]-AgCl and have demonstrated the influence of halide ions and the solvent on the structural formulas of Ag¹-NHCs. Similar results have been communicated by Fremont *et al.*[40] Ion-pair complexes have been obtained in the reaction of *N,N*-dimethylimidazoliumiodide with Ag₂O in dichloromethane (DCM).[41] Fluxional behavior between [R₂NHC] AgX and [(R₂NHC)₂ − Ag] + [AgX₂]− species was observed in solution for most of the complexes.[42] Mechanism of formation of silver *N*-heterocyclic carbenes was reported by Lin *et al.*[43] in 2007. According to these results, the monomeric compound NHC−Ag−X, in which the two ligands adopt a linear disposition, seems to be the most favorable species in CH₂Cl₂ solution.

Biological activities

All the synthesized benzimidazolium salts (**2a-2j**) and their corresponding silver(I) complexes (**3a-3j**) were investigated for antibacterial against the both gram (+)/(−) bacteria. The DMSO did not exhibit any antimicrobial activity as reported earlier.[44,45] The antimicrobial activities of the NHC precursors (**2a-2j**) and their corresponding silver complexes (**3a-3j**) are summarized in Table 2.

Compound **3i** is more active than compounds **3h** and **3c** against the *Micrococcus luteus* LB 14110. The complexes have shown antibacterial activity to different extents, depending on the nature of the ligand. On comparison with the benzimidazolium salts, the silver complexes have shown enhanced activity. The complexes exhibited enhanced antibacterial activity, which is due to the synergistic effect that increases the lipophilicity of the complexes. Observed

**Figure 1.** ^{1}H NMR spectra (400 MHz, CDCl$_3$) of silver complex **3c**.

Figure 2. ^{13}C NMR spectra (100 MHz, CDCl$_3$) of silver complex **3c**.

Table 1. Physical and spectroscopic properties of new benzimidazolium salts **2a-2j** and Ag^I complexes **3a-3j**

Compound	Molecular formula	Isolated yield / %	mp / °C	$v_{(CN)}$ / cm^{-1}	H(2) ^{1}H NMR / ppm	C(2) ^{13}C NMR / ppm
2a	$C_{21}H_{27}ClN_2O_3$	93	136.2	1437	12.02	144.1
2b	$C_{23}H_{31}ClN_2O_3$	92	198.2	1438	11.80	142.7
2c	$C_{22}H_{29}ClN_2$	97	217.2	1542	12.02	143.7
2d	$C_{24}H_{33}ClN_2$	98	243.2	1558	11.77	142.8
2e	$C_{21}H_{27}ClN_2$	94	218.3	1469	11.61	144.2
2f	$C_{21}H_{27}ClN_2$	93	223.3	1561	11.79	142.8
2g	$C_{22}H_{23}ClN_2$	89	146.4	1665	12.15	144.1
2h	$C_{26}H_{25}ClN_2$	89	278.9	1550	12.27	144.5
2i	$C_{14}H_{21}ClN_2O$	77	108.5	1567	11.46	143.9
2j	$C_{17}H_{27}ClN_2$	87	127.9	1666	11.26	142.1
3a	$C_{21}H_{26}AgClN_2O_3$	75	136.2	1567	–	not observed
3b	$C_{23}H_{30}AgClN_2O_3$	92	289.5	1583	–	not observed
3c	$C_{22}H_{28}AgClN_2$	78	108.6	1450	–	not observed
3d	$C_{24}H_{32}AgClN_2$	79	118.2	1450	–	not observed
3e	$C_{21}H_{26}AgClN_2$	74	194.2	1467	–	not observed
3f	$C_{21}H_{26}AgClN_2$	93	161.2	1433	–	not observed
3g	$C_{22}H_{22}AgClN_2$	76	195.4	1437	–	not observed
3h	$C_{26}H_{24}AgClN_2$	74	252.3	1450	–	not observed
3i	$C_{14}H_{20}AgClN_2O$	77	188.5	1433	–	not observed
3j	$C_{17}H_{26}AgClN_2$	72	168.9	1600	–	168.7

Table 2. Zone of bacterial inhibition of the synthesized salts **2** and silver complexes **3**

Compound	Zone of bacterial inhibition / mm				
	Micrococcus luteus (LB 14110)	*Listeria monocytogenes* (ATCC 19117)	*Salmonella* Typhimurium (ATCC 14028)	*Staphylococcus aureus* (ATCC 6538)	*Pseudomonas aeruginosa*
3a	21 ± 0.6	15 ± 0.5	19 ± 0.54	17 ± 0.25	17 ± 0.13
3b	23 ± 0.6	16 ± 0.6	19 ± 0.5	18 ± 0.3	18 ± 0.14
3c	36 ± 0.5	17 ± 0.2	19 ± 0.5	19 ± 0.5	23 ± 0.2
3d	31 ± 0.5	15 ± 0.5	17 ± 0.10	19 ± 0.11	17 ± 0.19
3e	26 ± 0.33	23 ± 0.5	19 ± 0.5	19 ± 0.18	21 ± 0.45
3f	37 ± 0.2	17 ± 0.3	19 ± 0.5	21 ± 0.1	21 ± 0.4
3g	29 ± 0.32	17 ± 0.5	23 ± 0.44	19 ± 0.15	23 ± 0.5
3h	31 ± 0.4	17 ± 0.2	17 ± 0.2	21 ± 0.2	19 ± 0.2
3i	39 ± 0.2	23 ± 0.2	23 ± 0.3	23 ± 0.2	21 ± 0.4
3j	35 ± 0.44	23 ± 0.5	23 ± 0.15	23 ± 0.3	21 ± 0.25
2a	21 ± 0.22	–	22 ± 0.22	18 ± 0.05	18 ± 0.22
2b	19 ± 0.2	20 ± 0.2	16 ± 0.3	20 ± 0.2	18 ± 0.2
2c	17 ± 0.2	18 ± 0.3	18 ± 0.22	16 ± 0.0	16 ± 0.5
2d	23 ± 0.2	17 ± 0.2	15 ± 0.2	21 ± 0.2	17 ± 0.2
2e	19 ± 0.2	19 ± 0.22	19 ± 0.33	19 ± 0.23	19 ± 0.22
2f	31 ± 0.4	23 ± 0.7	31 ± 0.4	26 ± 0.2	19 ± 0.22
2g	23 ± 0.3	17 ± 0.4	23 ± 0.4	19 ± 0.2	19 ± 0.2
2h	11 ± 0.4	15 ± 0.5	14 ± 0.10	15 ± 0.15	17 ± 0.10
2i	33 ± 0.32	–	17 ± 0.15	19 ± 0.1	19 ± 0.15
2j	21 ± 0.4	19 ± 0.5	19 ± 0.24	19 ± 0.5	20 ± 0.16
Fluconazole	24				

antibacterial activity of these complexes is comparable to that of previous silver complexes.[46]

MIC determination

The MIC values of tested silver complexes and their starting material against *Listeria monocytogenes* ATCC 19117, *Salmonella* Typhimurium ATCC 14028 and *Micrococcus luteus* are presented in Table 3.

Table 3. Minimal bacterial inhibitory concentration (MIC) of benzimidazoles salts and silver-NHC complexes

Microorganism indicator	Compound	MIC / (mg mL^{-1})
Listeria monocytogenes ATCC 19117	**2h**	1.25
	2j	0.635
	3f	0.0058
	ampicillin	0.049
Salmonella Typhimurium ATCC 14028	**2h**	1.26
	2j	0.041
	3f	0.0034
	ampicillin	0.635
Micrococcus luteus	**2h**	0.3225
	2j	0.3125
	3f	0.0034
	ampicillin	0.0195

Silver complex **3f** showed good activity than that of ampicillin against *Micrococcus luteus* with an MIC of 0.0034 mg mL^{-1}, while an MIC of 0.0034 mg mL^{-1} was observed in the case of *Salmonella* Typhimurium for the silver complex **3f**. MICs of other compounds remained within the tested range.

Cytotoxic activities

The benzimidazolium salts and their corresponding Ag^{I}–NHC complexes were screened colorimetrically using MTT cell assay in two human cancer cell lines, namely MCF7 and MDA-MB-231, to assess their cytotoxicity. The results are presented in Table 4.

As shown in Table 4, the cytotoxicity of **3i** and **3f** was much stronger in MCF7 with half-maximal inhibitory concentration (IC$_{50}$) values of 0.63 and 0.69 µg mL^{-1}, respectively, as compared to their activity on MDA-MB-231 cells. The cytotoxicity of compound **3j** in MCF7 and MDA-MB-231 cells was 1.4 and 3.5 µg mL^{-1}, while the IC$_{50}$ values of compound **2a** were 2.1 and 2.8 µg mL^{-1} against MCF7 and MDA-MB-231, respectively. The compound **2d** was inactive against MCF7.

Table 4. Anticancer activity of synthesized of benzimidazoles salts **2a-2j** and silver-NHC complexes **3a-3j**

Compound	Anticancer activity IC$_{50}$ / (µg mL^{-1})	
	MCF7	MDA-MB-231
3a	4.2 ± 3.5	4.3 ± 3.3
3b	4.1 ± 3.6	2.6 ± 4.3
3c	3.2 ± 3.1	2.7 ± 5.9
3d	1.8 ± 3.1	15 ± 2.8
3e	4.2 ± 1.8	0.0 ± 00
3f	0.69 ± 3.2	1.94 ± 2.6
3g	1.4 ± 4.1	3.4 ± 2.9
3h	2.1 ± 3.2	2.7 ± 2.9
3i	0.63 ± 3.1	1.96 ± 2.5
3j	1.4 ± 4.1	3.5 ± 2.9
2a	2.1 ± 3.2	2.8 ± 2.8
2b	NA	NA
2c	3.2 ± 5.9	6.2 ± 3.2
2d	NA	5.2 ± 3.1
2e	0.6 ± 2.9	3.1 ± 5.9
2f	> 100	> 100
2g	> 100	> 100
2h	> 100	> 100
2i	> 100	> 100
2j	> 100	> 100
Tetracycline[a]	NT	NT

[a]The concentration was 30 µg. NA: not active; IC$_{50}$: half maximal inhibitory concentration; MCF7 and MDA-MB-231: human cancer cell lines; NT: not tested. Values are mean value ± standard deviation of three different replicates.

Conclusions

In conclusion, a series of novel unsymmetrically substituted *N*-heterocyclic carbene precursors and their silver complexes were synthesized and characterized by ^{1}H NMR, ^{13}C NMR, IR and elemental analyses. New silver complexes showed high antibacterial activity compared with the precursors against gram (+)/(−) bacteria and fungi strains. In addition, the silver(I)-NHC complexes **3i** and **3f** showed good antitumor activity against MDA-MB-231, and MCF-7 cell lines. More studies are now in progress including a larger collection of bacteria of different species in order to determine if the antimicrobial activity is species dependent and its possible application in different fields. New biological active Pt or Au-NHC complexes will be prepared with the aim to develop robust cancer

chemotherapeutic agents. Furthermore, we will test the properties of both transmetallation reaction and catalysis of silver complexes described in this work.

Supplementary Information

Supplementary information is available free of charge at http://jbcs.sbq.org.br as PDF file.

Acknowledgments

Author Contributions

Ichraf Slimani was responsible for the formal analysis, investigation and methodology; Ahlem Chakchouk-Mtibaa, Lotfi Mellouli and Lamjed Mansour performed the biological study; Naceur Hamdi, Ismail Ozdemir and Nevin Gürbüz were responsible for the project administration, resources, software, validation, visualization, writing original draft, review and editing.

References

1. Liu, W.; Gust, R.; *Coord. Chem. Rev.* **2016**, *329*, 191.

2. Zou, T.; Ching, A.; Lum, T.; Lok, C. N.; Zhang, J. J.; Che, C. M.; *Chem. Soc. Rev.* **2015**, *44*, 8786.

3. Fricker, S. B.; *Dalton Trans.* **2007**, 4903.

4. Narasimhan, B.; Sharma, D.; Kumar, P.; *Med. Chem. Res.* **2012**, *21*, 269.

5. Haque, R. A.; Hasanudin, N.; Iqbal, M. A.; Ahmad, A.; Hashim, S.; Majid, A. A.; Ahamed, M. B. K.; *J. Coord. Chem.* **2013**, *66*, 3211.

6. Cachoux, F.; Isarno, T.; Wartmann, M.; Altmann, K. H.; *ChemBioChem* **2006**, *7*, 54.

7. Narasimhan, B.; Sharma, D.; Kumar, P.; *Med. Chem. Res.* **2011**, *20*, 1119.

8. Asif, M.; Iqbal, M. A.; Hussein, M. A.; Oon, C. E.; Haque, R. A.; Ahamed, M. B. K.; Majid, A. M. S. A.; *Eur. J. Med. Chem.* **2016**, *108*, 177.

9. Achar, G.; Shahini, C. R.; Patil, S. A.; Budagumpi, S.; *J. Organomet. Chem.* **2017**, *833*, 28.

10. Cheng, C. H.; Chen, D. F.; Song, H. B.; Tang, L. F.; *J. Organomet. Chem.* **2013**, *726*, 1.

11. Ozdemir, İ.; Demir, S.; Gunal, S.; Ozdemir, İ.; Arıcı, C.; Ulku, D.; *Inorg. Chim. Acta* **2010**, *363*, 3803.

12. Kaloğlu, M.; Kaloğlu, N.; Ozdemir, İ.; Gunal, S.; Ozdemir, İ.; *Bioorg. Med. Chem.* **2016**, *24*, 3649.

13. Napoli, M.; Saturnino, C.; Cianciulli, E. I.; Varcamonti, M.; Zanfardino, A.; Tommonaro, G.; Longo, P.; *J. Organomet. Chem.* **2013**, *725*, 46.

14. Muenzner, J. K.; Rehm, T.; Biersack, B.; Casini, A.; de Graaf, I. A.; Worawutputtapong, P.; Schobert, R.; *J. Med. Chem.* **2015**, *58*, 6283.

15. Streciwilk, W.; Terenzi, A.; Misgeld, R.; Frias, C.; Jones, P. G.; Prokop, A.; Ott, I.; *ChemMedChem* **2017**, *12*, 214.

16. Teyssot, M. L.; Jarrousse, A. S.; Chevry, A.; de Haze, A.; Beaudoin, C.; Manin, M.; Gautier, A.; *Chem. - Eur. J.* **2009**, *15*, 314.

17. Haque, R. A.; Budagumpi, S.; Choo, S. Y.; Choong, M. K.; Lokesh, B. E.; Sudesh, K.; *Appl. Organomet. Chem.* **2012**, *26*, 689.

18. Youn, S.; Yoo, H. J.; *Adv. Synth. Catal.* **2017**, *359*, 2176.

19. Frey, G. D.; Schutz, J.; Herdtweck, E.; Herrmann, W. A.; *Organometallics* **2005**, *24*, 4416.

20. Sahin, N.; Dusunceli, S. D.; Ozdemir, İ.; *Heterocycles* **2017**, *94*, 1506.

21. Haque, R. A.; Salman, A. W.; Budagumpi, S.; Abdullah, A. A. A.; Al-Mudaris, Z. A. A. H.; Majid, A. M. S. A.; *Appl. Organomet. Chem.* **2013**, *27*, 465.

22. Iacopetta, D.; Mariconda, A.; Saturnino, C.; Caruso, A.; Palma, G.; Ceramella, J.; Muià, N.; Perri, M.; Sinicropi, M. S.; Caroleo, M. C.; Longo, P.; *ChemMedChem* **2017**, *12*, 2054.

23. Saturnino, C.; Barone, I.; Iacopetta, D.; Mariconda, A.; Sinicropi, M. S.; Rosano, C.; Campana, A.; Catalano, S.; Longo, P.; Andò, S.; *Future Med. Chem.* **2016**, *8*, 2213.

24. Napoli, M.; Saturnino, C.; Sirignano, E.; Popolo, A.; Pinto, A.; Longo, P.; *Eur. J. Med. Chem.* **2011**, *46*, 122.

25. Rana, B. K.; Nandy, A.; Bertolasi, V.; Bielawski, W. C.; Saha, D. K.; Dinda, J.; *Organometallics* **2014**, *33*, 2544.

26. Dinda, J.; Nandy, A.; Rana, B. K.; Bertolasi, V.; Saha, D. K.; Bielawskief, W. C.; *RSC Adv.* **2014**, *105*, 60776.

27. Garrison, J. C.; Youngs, W. J.; *Chem. Rev.* **2005**, *105*, 3978.

28. da Silva, B.; Habibi, M.; Ognier, S.; Schelcher, G.; Mostafavi-Amjad, J.; Khalesifard, H. R. M.; Bonn, D.; *Eur. Phys. J.: Spec. Top.* **2016**, *225*, 707.

29. Varaprasad, K.; Mohan, Y. M.; Vimala, K.; Raju, K. M.; *J. Appl. Polym. Sci.* **2011**, *121*, 784.

30. Mirsattari, S. M.; Hammond, R. R.; Sharpe, M. D.; Leung, F. Y.; Young, G. B.; *Neurology* **2004**, *62*, 1408.

31. Tagg, J. R.; McGiven, A. R.; *Appl. Microbiol.* **1971**, *21*, 943.

32. National Committee for Clinical Laboratory Standards (NCCLS); M7-A6: *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*, 6th ed.; NCCLS: Wayne, 2005.

33. National Committee for Clinical Laboratory Standards (NCCLS); M38-P: *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi*; NCCLS: Wayne, 1998.

34. Gulluce, M.; Sahin, F.; Sokmen, M.; Ozer, H.; Daferera, D.; Sokmen, A.; Polissiou, M.; Adiguzel, A.; Ozkan, H.; *Food Chem.* **2007**, *103*, 1449.

35. Kirby, A. J.; Schmidt, R. J.; *J. Ethnopharmacol.* **1997**, *56*, 103.

36. Mosmann, T.; *J. Immunol. Methods* **1983**, *65*, 55.

37. Miles, A. A.; Misrna, S. S.; Irwin, J. O.; *J. Hyg.* **1938**, *38*, 732.

38. Zonouzi, A.; Mirzazadeh, R.; Safavi, M.; Kabudanian, S. A.; Emami, S.; Foroumadi, A.; *Iran. J. Pharm. Res.* **2013**, *12*, 679.

39. Asekunowo, P. O.; Haque, R. A.; Razali, M. R.; Budagumpi, S.; *Appl. Organomet. Chem.* **2015**, *29*, 126.

40. Fremont, P.; Scott, N. M.; Stevens, E. D.; Rammnial, T.; Lightbody, O. C.; Macdonald, C. L. B.; Clyburne, J. A. C.; Abernethy, C. D.; Nolan, S. P.; *Organometallics* **2005**, *24*, 6301.

41. Chiu, P. L.; Chen, C. Y.; Lee, C. C.; Hsieh, M. H.; Chuang, C. H.; Lee, H. M.; *Inorg. Chem.* **2006**, *45*, 2520.

42. Chen, W.; Liu, F.; *J. Organomet. Chem.* **2003**, *673*, 5.

43. Lin, I. J. B.; Vasam, C. S.; *Comments Inorg. Chem.* **2004**, *25*, 75.

44. Hayes, J. M.; Viciano, M.; Peris, E.; Ujaque, G.; Lledós, A.; *Organometallics* **2007**, *26*, 6170.

45. Slawson, R. M.; Van Dyke, M. I.; Lee, H.; Trevors, J. T.; *Plasmid* **1992**, *27*, 72.

46. Zhao, G.; Stevens, S. E.; *BioMetals* **1998**, *11*, 27.